Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Incyte Corp ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 58.53 |
| Open* | 58.53 |
| 1-Year Change* | -13.42% |
| Day's Range* | 57.95 - 58.53 |
| 52 wk Range | 60.56-86.29 |
| Average Volume (10 days) | 1.54M |
| Average Volume (3 months) | 37.32M |
| Market Cap | 14.22B |
| P/E Ratio | 38.98 |
| Shares Outstanding | 224.09M |
| Revenue | 3.51B |
| EPS | 1.63 |
| Dividend (Yield %) | N/A |
| Beta | 0.69 |
| Next Earnings Date | Oct 30, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 28, 2023 | 58.53 | -0.22 | -0.37% | 58.75 | 59.22 | 58.35 |
| Sep 27, 2023 | 59.03 | -0.16 | -0.27% | 59.19 | 59.78 | 58.65 |
| Sep 26, 2023 | 59.19 | 1.02 | 1.75% | 58.17 | 59.57 | 58.02 |
| Sep 25, 2023 | 58.68 | 1.05 | 1.82% | 57.63 | 58.77 | 57.43 |
| Sep 22, 2023 | 58.03 | -0.42 | -0.72% | 58.45 | 59.21 | 57.86 |
| Sep 21, 2023 | 58.70 | -1.35 | -2.25% | 60.05 | 60.24 | 58.69 |
| Sep 20, 2023 | 60.29 | 0.49 | 0.82% | 59.80 | 60.93 | 59.79 |
| Sep 19, 2023 | 60.51 | 1.26 | 2.13% | 59.25 | 60.77 | 59.23 |
| Sep 18, 2023 | 59.44 | -0.11 | -0.18% | 59.55 | 59.98 | 58.21 |
| Sep 15, 2023 | 62.46 | -0.54 | -0.86% | 63.00 | 63.80 | 62.25 |
| Sep 14, 2023 | 63.39 | 0.57 | 0.91% | 62.82 | 63.79 | 62.60 |
| Sep 13, 2023 | 63.02 | -0.96 | -1.50% | 63.98 | 64.50 | 62.84 |
| Sep 12, 2023 | 64.15 | 0.15 | 0.23% | 64.00 | 64.59 | 63.56 |
| Sep 11, 2023 | 64.32 | 0.55 | 0.86% | 63.77 | 64.77 | 63.58 |
| Sep 8, 2023 | 63.89 | 0.47 | 0.74% | 63.42 | 64.28 | 63.42 |
| Sep 7, 2023 | 63.37 | 0.49 | 0.78% | 62.88 | 63.48 | 62.62 |
| Sep 6, 2023 | 63.12 | 0.09 | 0.14% | 63.03 | 63.45 | 62.41 |
| Sep 5, 2023 | 63.19 | -0.79 | -1.23% | 63.98 | 65.08 | 63.16 |
| Sep 1, 2023 | 64.61 | 0.04 | 0.06% | 64.57 | 65.36 | 64.39 |
| Aug 31, 2023 | 64.44 | -0.63 | -0.97% | 65.07 | 65.28 | 64.27 |
Incyte Corporation Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, October 30, 2023 | ||
| Time (UTC) 11:00 | Country US
| Event Q3 2023 Incyte Corp Earnings Release Q3 2023 Incyte Corp Earnings ReleaseForecast -Previous - |
| Monday, February 5, 2024 | ||
| Time (UTC) 12:00 | Country US
| Event Q4 2023 Incyte Corp Earnings Release Q4 2023 Incyte Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3394.64 | 2986.27 | 2666.7 | 2158.76 | 1881.88 |
| Revenue | 3394.64 | 2986.27 | 2666.7 | 2158.76 | 1881.88 |
| Cost of Revenue, Total | 185.497 | 129.491 | 109.828 | 92.749 | 72.623 |
| Gross Profit | 3209.14 | 2856.78 | 2556.87 | 2066.01 | 1809.26 |
| Total Operating Expense | 2815.2 | 2400.49 | 2930.38 | 1756.75 | 1752.66 |
| Selling/General/Admin. Expenses, Total | 1002.14 | 739.56 | 516.922 | 468.711 | 434.407 |
| Research & Development | 1585.94 | 1458.18 | 2215.94 | 1154.11 | 1197.96 |
| Depreciation / Amortization | 21.5 | 21.5 | 21.5 | 21.5 | 21.5 |
| Unusual Expense (Income) | 20.122 | 51.76 | 66.186 | 19.682 | 26.173 |
| Operating Income | 579.44 | 585.777 | -263.676 | 402.006 | 129.223 |
| Interest Income (Expense), Net Non-Operating | -90.256 | -25.98 | 31.458 | 84.785 | -45.636 |
| Net Income Before Taxes | 529.116 | 570.444 | -232.218 | 486.791 | 115.347 |
| Net Income After Taxes | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Net Income Before Extra. Items | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Net Income | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Income Available to Common Excl. Extra. Items | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Income Available to Common Incl. Extra. Items | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Dilution Adjustment | |||||
| Diluted Net Income | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Diluted Weighted Average Shares | 223.958 | 222.074 | 218.073 | 217.657 | 215.635 |
| Diluted EPS Excluding Extraordinary Items | 1.52109 | 4.27146 | -1.35595 | 2.05326 | 0.50777 |
| Diluted Normalized EPS | 1.57893 | 4.42296 | -1.15868 | 2.13628 | 0.62299 |
| Other, Net | 39.932 | 10.647 | 31.76 | ||
| Total Extraordinary Items | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 954.61 | 808.673 | 926.7 | 823.303 | 911.397 |
| Revenue | 954.61 | 808.673 | 926.7 | 823.303 | 911.397 |
| Cost of Revenue, Total | 62.626 | 51.422 | 53.763 | 49.284 | 45.236 |
| Gross Profit | 891.984 | 757.251 | 872.937 | 774.019 | 866.161 |
| Total Operating Expense | 760.83 | 783.903 | 856.607 | 684.927 | 656.966 |
| Selling/General/Admin. Expenses, Total | 283.929 | 315.606 | 272.819 | 266.46 | 253.277 |
| Research & Development | 400.75 | 406.641 | 501.36 | 384.007 | 347.196 |
| Depreciation / Amortization | 5.7 | 5.4 | 5.4 | 5.3 | 5.4 |
| Unusual Expense (Income) | 7.825 | 4.834 | 23.265 | -20.124 | 5.857 |
| Operating Income | 193.78 | 24.77 | 70.093 | 138.376 | 254.431 |
| Interest Income (Expense), Net Non-Operating | 41.156 | -5.787 | -16.115 | -1.301 | -25.575 |
| Other, Net | 42.668 | 32.873 | 26.637 | 11.513 | 0.522 |
| Net Income Before Taxes | 277.604 | 51.856 | 80.615 | 148.588 | 229.378 |
| Net Income After Taxes | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Net Income Before Extra. Items | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Net Income | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Income Available to Common Excl. Extra. Items | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Income Available to Common Incl. Extra. Items | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Diluted Net Income | 203.548 | 21.703 | 28.461 | 112.775 | 161.432 |
| Diluted Weighted Average Shares | 225.649 | 225.589 | 224.954 | 224.175 | 223.661 |
| Diluted EPS Excluding Extraordinary Items | 0.90206 | 0.09621 | 0.12652 | 0.50307 | 0.72177 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.92748 | 0.10517 | 0.19374 | 0.43493 | 0.7402 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 4092.85 | 3118.67 | 2359.89 | 2481.49 | 1832.25 |
| Cash and Short Term Investments | 3238.97 | 2348.19 | 1801.38 | 2117.55 | 1438.32 |
| Cash & Equivalents | 2951.42 | 2057.44 | 1513.01 | 1832.68 | 1163.98 |
| Short Term Investments | 287.543 | 290.752 | 288.369 | 284.87 | 274.343 |
| Total Receivables, Net | 644.879 | 616.3 | 481.994 | 308.809 | 307.598 |
| Accounts Receivable - Trade, Net | 644.879 | 616.3 | 481.794 | 308.409 | 306.898 |
| Total Inventory | 41.995 | 27.904 | 16.425 | 11.4 | 6.967 |
| Prepaid Expenses | 167.011 | 126.278 | 60.098 | 43.725 | 79.366 |
| Other Current Assets, Total | |||||
| Total Assets | 5840.98 | 4933.35 | 3560.92 | 3426.75 | 2645.76 |
| Property/Plant/Equipment, Total - Net | 765.608 | 751.468 | 588.076 | 406.625 | 319.751 |
| Property/Plant/Equipment, Total - Gross | 978.422 | 927.188 | 732.45 | 528.495 | 422.982 |
| Accumulated Depreciation, Total | -212.814 | -175.72 | -144.374 | -121.87 | -103.231 |
| Goodwill, Net | 155.593 | 155.593 | 155.593 | 155.593 | 155.593 |
| Intangibles, Net | 129.219 | 150.755 | 172.291 | 193.828 | 215.364 |
| Long Term Investments | 133.676 | 221.266 | 222.301 | 133.657 | 99.199 |
| Other Long Term Assets, Total | 564.038 | 535.596 | 62.763 | 55.559 | 23.601 |
| Total Current Liabilities | 1157.08 | 854.308 | 631.195 | 513.34 | 425.277 |
| Accounts Payable | 277.546 | 172.11 | 98.767 | 83.647 | 103.827 |
| Accrued Expenses | 575.634 | 460.262 | 370.729 | 274.741 | 191.572 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 300.718 | 219.301 | 159.415 | 135.988 | 111.182 |
| Total Liabilities | 1470.86 | 1163.35 | 949.65 | 828.344 | 719.795 |
| Total Long Term Debt | 30.083 | 31.632 | 32.573 | 31.918 | 17.434 |
| Long Term Debt | 0 | 0 | 17.434 | ||
| Other Liabilities, Total | 283.705 | 277.408 | 285.882 | 283.086 | 277.084 |
| Total Equity | 4370.12 | 3770 | 2611.27 | 2598.41 | 1925.97 |
| Common Stock | 0.223 | 0.221 | 0.219 | 0.216 | 0.213 |
| Additional Paid-In Capital | 4792.04 | 4567.11 | 4352.86 | 4044.49 | 3813.68 |
| Retained Earnings (Accumulated Deficit) | -437.214 | -777.874 | -1726.45 | -1430.76 | -1877.76 |
| Other Equity, Total | 15.069 | -19.454 | -15.36 | -15.542 | -10.165 |
| Total Liabilities & Shareholders’ Equity | 5840.98 | 4933.35 | 3560.92 | 3426.75 | 2645.76 |
| Total Common Shares Outstanding | 222.747 | 221.084 | 219.489 | 216.178 | 213.275 |
| Current Port. of LT Debt/Capital Leases | 3.179 | 2.635 | 2.284 | 18.964 | 18.696 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 30.083 | 31.632 | 32.573 | 31.918 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 3971.63 | 4092.85 | 3821.11 | 3625.84 | 3288.09 |
| Cash and Short Term Investments | 3112.71 | 3238.97 | 2977.12 | 2722.43 | 2544.16 |
| Cash & Equivalents | 2821.05 | 2951.42 | 2690.62 | 2435.38 | 2256.76 |
| Short Term Investments | 291.661 | 287.543 | 286.5 | 287.044 | 287.401 |
| Total Receivables, Net | 623.788 | 644.879 | 618.188 | 682.968 | 562.344 |
| Accounts Receivable - Trade, Net | 623.788 | 644.879 | 618.188 | 682.968 | 562.344 |
| Total Inventory | 40.876 | 41.995 | 45.869 | 54.502 | 35.457 |
| Prepaid Expenses | 194.257 | 167.011 | 179.932 | 165.95 | 146.13 |
| Total Assets | 5797.62 | 5840.98 | 5510.21 | 5319.04 | 5054.22 |
| Property/Plant/Equipment, Total - Net | 767.55 | 765.608 | 742.412 | 748.677 | 756.609 |
| Property/Plant/Equipment, Total - Gross | 993.226 | 978.422 | 944.392 | 940.535 | 942.42 |
| Accumulated Depreciation, Total | -225.676 | -212.814 | -201.98 | -191.858 | -185.811 |
| Goodwill, Net | 155.593 | 155.593 | 155.593 | 155.593 | 155.593 |
| Intangibles, Net | 140.658 | 129.219 | 134.603 | 139.987 | 145.371 |
| Long Term Investments | 128.313 | 133.676 | 149.124 | 149.784 | 174.681 |
| Other Long Term Assets, Total | 633.876 | 564.038 | 507.371 | 499.149 | 533.876 |
| Total Current Liabilities | 1006.11 | 1157.08 | 1006.6 | 926.674 | 886.163 |
| Accounts Payable | 55.633 | 277.546 | 163.175 | 194.77 | 152.547 |
| Accrued Expenses | 559.485 | 575.634 | 555.857 | 493.019 | 455.656 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3.149 | 3.179 | 3.112 | 3.036 | 2.796 |
| Other Current Liabilities, Total | 387.844 | 300.718 | 284.452 | 235.849 | 275.164 |
| Total Liabilities | 1335.06 | 1470.86 | 1283.56 | 1233.97 | 1191.15 |
| Total Long Term Debt | 29.699 | 30.083 | 30.476 | 31.157 | 31.385 |
| Capital Lease Obligations | 29.699 | 30.083 | 30.476 | 31.157 | 31.385 |
| Other Liabilities, Total | 299.245 | 283.705 | 246.491 | 276.143 | 273.601 |
| Total Equity | 4462.57 | 4370.12 | 4226.65 | 4085.06 | 3863.07 |
| Common Stock | 0.223 | 0.223 | 0.222 | 0.222 | 0.221 |
| Additional Paid-In Capital | 4856.91 | 4792.04 | 4721.17 | 4688.98 | 4625.78 |
| Retained Earnings (Accumulated Deficit) | -415.511 | -437.214 | -465.675 | -578.45 | -739.882 |
| Other Equity, Total | 20.942 | 15.069 | -29.062 | -25.696 | -23.047 |
| Total Liabilities & Shareholders’ Equity | 5797.62 | 5840.98 | 5510.21 | 5319.04 | 5054.22 |
| Total Common Shares Outstanding | 223.062 | 222.747 | 222.455 | 221.875 | 221.41 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 340.66 | 948.581 | -295.697 | 446.906 | 109.493 |
| Cash From Operating Activities | 969.941 | 749.488 | -124.599 | 710.656 | 336.227 |
| Cash From Operating Activities | 67.855 | 57.844 | 51.807 | 54.533 | 54.969 |
| Deferred Taxes | 57.091 | -465.604 | -0.35 | -0.377 | -0.459 |
| Non-Cash Items | 305.525 | 223.236 | 191.382 | 152.299 | 218.763 |
| Cash Taxes Paid | 136.242 | 67.731 | 70.712 | 33.553 | 5.417 |
| Cash Interest Paid | 0.396 | 0.194 | 0.239 | 0.268 | |
| Changes in Working Capital | 198.81 | -14.569 | -71.741 | 57.295 | -46.539 |
| Cash From Investing Activities | -78.542 | -207.699 | -269.001 | -87.454 | -86.423 |
| Capital Expenditures | -77.833 | -181.006 | -187.379 | -78.064 | -73.483 |
| Other Investing Cash Flow Items, Total | -0.709 | -26.693 | -81.622 | -9.39 | -12.94 |
| Cash From Financing Activities | -0.794 | 6.176 | 71.709 | 45.711 | 14.657 |
| Financing Cash Flow Items | -59.047 | -50.033 | -37.76 | -16.766 | -15.285 |
| Issuance (Retirement) of Stock, Net | 61.115 | 58.626 | 110.305 | 63.299 | 29.942 |
| Issuance (Retirement) of Debt, Net | -2.862 | -2.417 | -0.836 | -0.822 | 0 |
| Foreign Exchange Effects | 3.355 | -3.57 | 2.949 | -0.192 | 0.091 |
| Net Change in Cash | 893.96 | 544.395 | -318.942 | 668.721 | 264.552 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 21.703 | 340.66 | 312.199 | 199.424 | 37.992 |
| Cash From Operating Activities | -105.603 | 969.941 | 686.279 | 389.898 | 215.741 |
| Cash From Operating Activities | 19.211 | 67.855 | 49.637 | 32.945 | 16.438 |
| Non-Cash Items | 62.242 | 305.525 | 210.782 | 179.981 | 98.899 |
| Cash Taxes Paid | 7.107 | 136.242 | 116.537 | 76.464 | 3.472 |
| Changes in Working Capital | -186.596 | 198.81 | 73.229 | -54.927 | 60.306 |
| Cash From Investing Activities | -28.559 | -78.542 | -57.63 | -29.228 | -16.748 |
| Capital Expenditures | -11.906 | -77.833 | -56.56 | -28.749 | -17.006 |
| Other Investing Cash Flow Items, Total | -16.653 | -0.709 | -1.07 | -0.479 | 0.258 |
| Cash From Financing Activities | 4.009 | -0.794 | 1.686 | 15.997 | 0.096 |
| Financing Cash Flow Items | -9.177 | -59.047 | -39.197 | -20.327 | -15.634 |
| Issuance (Retirement) of Stock, Net | 13.988 | 61.115 | 42.989 | 37.692 | 16.398 |
| Issuance (Retirement) of Debt, Net | -0.802 | -2.862 | -2.106 | -1.368 | -0.668 |
| Foreign Exchange Effects | -0.199 | 3.355 | 2.728 | 1.198 | 0.21 |
| Net Change in Cash | -130.352 | 893.96 | 633.063 | 377.865 | 199.299 |
| Deferred Taxes | -22.163 | 57.091 | 40.432 | 32.475 | 2.106 |
| Cash Interest Paid |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | Hedge Fund | 16.1446 | 36178056 | 2656 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.7209 | 21783416 | 116771 | 2023-06-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 8.6029 | 19277960 | -54350 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.0749 | 15853966 | 2049984 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.3958 | 9850455 | 527398 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 2.1546 | 4828189 | -774244 | 2023-06-30 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 1.8732 | 4197574 | 2411239 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8196 | 4077490 | 115748 | 2023-06-30 | LOW |
| Invesco Capital Management LLC | Investment Advisor | 1.5134 | 3391414 | -117914 | 2023-06-30 | LOW |
| Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.1899 | 2666339 | 517858 | 2023-06-30 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 1.1785 | 2640765 | -199735 | 2023-06-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.9899 | 2218172 | 461827 | 2023-06-30 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.9416 | 2110055 | -106086 | 2023-06-30 | LOW |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.8597 | 1926547 | 103516 | 2023-06-30 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 0.8155 | 1827413 | 1793088 | 2023-06-30 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.8057 | 1805514 | 931571 | 2023-06-30 | HIGH |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7987 | 1789723 | 238045 | 2023-06-30 | LOW |
| Armistice Capital LLC | Hedge Fund | 0.7925 | 1776000 | -96000 | 2023-06-30 | HIGH |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7747 | 1735994 | 223560 | 2023-06-30 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.7649 | 1713953 | 290233 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com